Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis
| Autor: | John A. Lust, Suzanne R. Hayman, Surendra Dasari, David L. Murray, Eli Muchtar, Dragan Jevremovic, A L Fonder, Francis K. Buadi, Miriam Hobbs, Yi Lisa Hwa, Mindy C. Kohlhagen, Martha Q. Lacy, Steven R. Zeldenrust, David Dingli, Angela Dispenzieri, Nelson Leung, Steve Russell, Ronald S. Go, Morie A. Gertz, Taxiarchis Kourelis, Bonnie K. Arendt, Robert A. Kyle, Shaji Kumar, Wilson I. Gonsalves, S. Vincent Rajkumar, Rahma Warsame, Prashant Kapoor |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Pathology medicine.medical_specialty Neoplasm Residual Electrospray ionization Myeloma Plasma cell Mass spectrometry lcsh:RC254-282 Mass Spectrometry Article Biomarkers Tumor medicine AL amyloidosis Humans Immunoglobulin Light-chain Amyloidosis Aged Retrospective Studies Aged 80 and over business.industry Amyloidosis Hematology Middle Aged Prognosis medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Hematologic Response Survival Rate medicine.anatomical_structure Oncology Female Bone marrow business Complete Hematologic Response Chromatography Liquid Follow-Up Studies |
| Zdroj: | Blood Cancer Journal, Vol 10, Iss 2, Pp 1-5 (2020) Blood Cancer Journal |
| ISSN: | 2044-5385 |
| Popis: | In patients with immunoglobulin light-chain (AL) amyloidosis, depth of hematologic response correlates with both organ response and overall survival. Our group has demonstrated that screening with a matrix-assisted laser desorption/ionization-time-of-flight (TOF) mass spectrometry (MS) is a quick, sensitive, and accurate means to diagnose and monitor the serum of patients with plasma cell disorders. Microflow liquid chromatography coupled with electrospray ionization and quadrupole TOF MS adds further sensitivity. We identified 33 patients with AL amyloidosis who achieved amyloid complete hematologic response, who also had negative bone marrow by six-color flow cytometry, and who had paired serum samples to test by MS. These samples were subjected to blood MS. Four patients (12%) were found to have residual disease by these techniques. The presence of residual disease by MS was associated with a poorer time to progression (at 50 months 75% versus 13%, p = 0.003). MS of the blood out-performed serum and urine immunofixation, the serum immunoglobulin free light chain, and six-color flow cytometry of the bone marrow in detecting residual disease. Additional studies that include urine MS and next-generation techniques to detect clonal plasma cells in the bone marrow will further elucidate the full potential of this technique. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|